标准简介
ISO 14971:2019 是由 国际标准化组织 (ISO) 发布的有效标准，常用于医疗器械、医疗健康、科技等行业，并适用于全球等市场。
本页汇总了 ISO 14971:2019 的官方文档、当前状态以及常见相关认证或评估机构，便于快速理解要求与落地路径。
Full Lifecycle Coverage
Applies risk management across the entire medical device lifecycle — from initial concept and design through production, post-market surveillance, and decommissioning.
Benefit-Risk Analysis
The 2019 edition places greater emphasis on the overall benefit-risk ratio, requiring manufacturers to weigh clinical benefits against residual risks systematically.
Continuous Process
Risk management is not a one-time activity but an ongoing process that integrates post-production information and state-of-the-art knowledge into risk evaluations.
list_alt Risk Management Process Steps
- Risk management planning and scope definition
- Hazard identification and hazardous situation analysis
- Risk estimation and risk evaluation against acceptability criteria
- Risk control option analysis and implementation
- Evaluation of overall residual risk
- Risk management review and reporting
- Production and post-production information collection
- Integration with ISO 13485 quality management system
谁需要合规？
All medical device manufacturers, including software-as-a-medical-device (SaMD) and in vitro diagnostic (IVD) device makers. Required by the EU MDR, FDA, and most global regulatory frameworks.
关键要求
Risk Management Plan
Establish a documented risk management plan defining scope, responsibilities, risk acceptability criteria, verification activities, and review requirements for the entire product lifecycle.
Hazard Identification & Risk Analysis
Systematically identify known and foreseeable hazards in both normal and fault conditions. Estimate risks by analyzing severity of harm and probability of occurrence for each hazardous situation.
Risk Control Measures
Implement risk controls following the priority hierarchy: inherent safety by design, protective measures in the device or manufacturing process, and information for safety (labeling, instructions).
Overall Residual Risk Evaluation
Evaluate the overall residual risk from all identified hazards after all risk control measures are applied, and determine whether the medical benefits outweigh the remaining risks.
Post-Production Monitoring
Collect and review production and post-production information including complaint data, incident reports, and published literature to identify previously unrecognized hazards or risks.
实施路线图
定义医疗器械风险管理范围
识别 ISO 14971:2019 覆盖的产品、服务、场所、系统、团队、司法辖区和相关方。确认责任人、边界、适用义务、文件和证据期望，范围包括危险识别、可预见误用、风险估计、风险评价、风险控制、剩余风险可接受性、收益风险分析、生产信息和上市后监视。
评估差距并排列风险优先级
将当前实践与预期的医疗器械风险管理方法进行比较。审查风险管理计划、危险分析、控制验证、剩余风险评价、风险管理报告、生产反馈和上市后监督关联，并按法律暴露、安全影响、客户承诺、运营依赖以及审核或市场准入准备度排列差距优先级。
实施控制和记录
部署所需程序、技术控制、评审关口、培训、供应商流程、报告路径和运行记录。维护风险管理文件、危险分析、FMEA 或等效分析、验证记录、收益风险决策、可用性关联、投诉数据和上市后评审作为可追溯证据。
评审、审核并改进
开展内部评审、管理报告、审核、纠正措施和变更评估。当产品、服务、供应商、技术、法规、事件或相关方期望变化时刷新项目。
合规检查清单
checklist 范围与治理
checklist 控制与证据
checklist 监控与改进
处罚与执行
No direct penalties for non-compliance with the standard itself. However, failure to demonstrate adequate risk management can result in rejection of regulatory submissions, product recalls, and market access denial under the EU MDR, FDA 21 CFR 820, and other regulations.
常见问题解答
谁需要 ISO 14971:2019？
expand_more
ISO 14971:2019 最适用于在全生命周期管理产品风险的医疗器械和 IVD 制造商。具体范围取决于产品、服务、司法辖区、客户承诺，以及组织是否需要认证、符合性证据、监管准备或内部治理。
ISO 14971:2019 是否可认证？
expand_more
ISO 14971 通常通过医疗器械 QMS 和监管审核进行检查，而不是单独认证。
实施时应先关注什么？
expand_more
先定义范围和义务，再建立当前状态差距评估。早期最重要的工作是确认责任、受影响资产或过程、风险准则、客户或法律驱动因素，以及组织必须能够提供的证据。
ISO 14971:2019 需要哪些证据？
expand_more
有用证据包括风险管理文件、危险分析、FMEA 或等效分析、验证记录、收益风险决策、可用性关联、投诉数据和上市后评审。证据应进行版本控制，能够追溯到责任人，并关联风险、义务、控制、决策和纠正措施。
项目应多久评审一次？
expand_more
应按计划周期评审，并在产品、服务、供应商、运行环境、事件、客户承诺或法规变化时评审。高风险领域应采用更频繁的监控和管理报告。